Endocrine system

Endocrine system - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Alogliptin (Vipidia®) tablets for the treatment of type 2 diabetes Dulaglutide (Trulicity®) for the treatment of type 2 diabetes Insulin Degludec 100units/ml (Tresiba®) for Type 1 Diabetes Insulin Degludec for Type 2 Diabetes Lixisenatide for type 2 diabetes

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Rate this page